Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 Weeks of Combined Treatment of Patients Receiving Pegasys and Copegus Who Are Biochemical Responders But Virological Non-Responders at Week 12 or Week 24

NCT00336518 is registered in ClinicalTrials.gov with Májbetegekért Alapítvány as lead sponsor.

NCT NCT00336518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00336518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 Weeks of Combined Treatment of Patients Receiving Pegasys and Copegus Who Are Biochemical Responders But Virological Non-Responders at Week 12 or Week 24
Lead sponsor
Májbetegekért Alapítvány
Phase
Phase 3
Overall status
Unknown status
Start date
June 30, 2006
Completion date
July 31, 2009
Enrollment
100
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c